Table 2 Incidence of all-grade TRAEs ≥ 10% and grade 3 or higher TRAEs ≥ 3%

From: Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

TEAE, n (%)

Safety population (n = 150)

B2 cohort (n = 121)

All grade

Grade ≥ 3

All grade

Grade ≥ 3

Any

147 (98.0)

93 (62.0)

119 (98.3)

79 (65.3)

Rash

118 (78.7)

32 (21.3)

96 (79.3)

26 (21.5)

Diarrhea

98 (65.3)

16 (10.7)

80 (66.1)

14 (11.6)

Dry skin

88 (58.7)

7 (4.7)

67 (55.4)

5 (4.1)

Decreased appetite

85 (56.7)

4 (2.7)

67 (55.4)

3 (2.5)

Paronychia

81 (54.0)

3 (2.0)

64 (52.9)

2 (1.7)

AST increased

57 (38.0)

2 (1.3)

44 (36.4)

2 (1.7)

ALT increased

54 (36.0)

0

44 (36.4)

0

Weight decreased

52 (34.7)

6 (4.0)

50 (41.3)

6 (5.0)

Vomiting

50 (33.3)

3 (2.0)

39 (32.2)

3 (2.5)

Oral mucositis

47 (31.3)

4 (2.7)

37 (30.6)

3 (2.5)

Nausea

43 (28.7)

1 (0.8)

36 (29.8)

1 (0.7)

Pruritus

42 (28.0)

2 (1.3)

29 (24.0)

2 (1.7)

Anemia

40 (26.7)

5 (3.3)

33 (27.3)

4 (3.3)

Malaise

39 (26.0)

5 (3.3)

29 (24.0)

5 (4.1)

White blood cell decreased

37 (24.7)

4 (2.7)

33 (27.3)

4 (3.3)

Platelet count decreased

36 (24.0)

7 (4.7)

35 (28.9)

6 (5.0)

Hypoalbuminemia

36 (24.0)

0

28 (23.1)

0

Neutrophil count decreased

29 (19.3)

8 (5.3)

28 (23.1)

8 (6.6)

Fever

29 (19.3)

0

21 (17.4)

0

Skin hypopigmentation

29 (19.3)

0

21 (17.4)

0

Dizziness

26 (17.3)

0

18 (14.9)

0

Hyponatremia

24 (16.0)

1 (0.7)

20 (16.5)

1 (0.8)

Proteinuria

22 (14.7)

0

21 (17.4)

0

Stomal ulcer

22 (14.7)

0

20 (16.5)

0

Hypokalemia

21 (14.0)

2 (1.3)

10 (8.3)

0

CPK increased

20 (13.3)

5 (3.3)

20 (16.5)

5 (4.1)

Headache

19 (12.7)

1 (0.7)

12 (9.9)

1 (0.8)

Skin fissures

18 (12.0)

0

16 (13.2)

0

QT interval prolonged

16 (10.7)

0

16 (13.2)

0

Blood LDH increased

16 (10.7)

0

14 (11.6)

0

Blood creatinine increased

16 (10.7)

0

13 (10.7)

0

Hypocalcemia

15 (10.0)

0

14 (11.6)

0

  1. TRAEs treatment-related adverse events, AST aspartate aminotransferase, ALT alanine aminotransferase, CPK creatine phosphate kinase, LDH lactate dehydrogenase.
Back to article page